Intellectual Product – Page 6

Lilly Posts Encouraging Early-Stage Weight Loss Data on Amylin Candidate

2 months ago talkbio0Tagged Amylin Candidate, aspects of adverse effects, Clinical Data, early-stage trial, Eli, Eli Lilly, Eloralintide, Obesity, Weight Loss

Eli Lilly; eloralintide; amylin candidate; weight loss; early-stage trial; obesity drug; clinical data; side effects

Best Practice Customer-Facing Organization Study Report (2025) – Key Findings and Trends

3 months ago talkbio0Tagged Aortic Valve Insufficiency, Customer, customer-facing organization, Cytology diagnosis, digital transformation, DNA Integration, Optimization, Practice Experience, Report (document), self-service

customer-facing organization; best practices; 2025 report; customer experience; self-service; AI integration; CX optimization; digital transformation

FDA Reinstates Generic Drug Policy Group After April Firings

3 months ago talkbio0Tagged Administrative action, Departure - action, development aspects, drug price, Generic Drugs, layoffs, Office, Policy, reinstatement, Transection (procedure), United States Food and Drug Administration

FDA; generic drugs; policy office; Division of Policy Development; reinstatement; layoffs; drug prices; administrative leave

Inside ASCO 2025: Big Data Drops and a Towering Campaign – Key News Highlights

3 months ago talkbio0Tagged 2025, Artificial Intelligence, ASCO, Big Data, campaigns, Cancer Research, Clinical Oncology, erbB-2 Receptor, Malignant neoplasm of breast, Malignant neoplasm of lung

ASCO 2025; cancer research; big data; campaigns; clinical oncology; artificial intelligence; HER2; lung cancer; breast cancer; therapeutic vaccines

Axsome Plots New Fibromyalgia Trial After FDA Refuses Review of Former Pfizer Candidate

3 months ago talkbio0Tagged Analgesics, AXS-14, Axsome, Clinical Trials, esreboxetine, Fibromyalgia, File (record), Pfizer, refusal, trial design, United States Food and Drug Administration

Axsome Therapeutics; esreboxetine; fibromyalgia; FDA; refusal to file; clinical trial; Pfizer; AXS-14; trial design; pain medicine

Federally-Funded Cancer Research at a Perilous Crossroads: Deep Cuts Threaten Progress

3 months ago talkbio0Tagged AACR, Budgets, Cancer Research, Congress (U.S. Legislature), federal, Funding, Malignant neoplasm of lung, NIH Mouse, Pancreatic carcinoma, public health policy

federal funding; cancer research; NIH budget cuts; Congress; lung cancer; pancreatic cancer; AACR; public health policy

Corcept Highlights Survival Benefit Despite ALS Trial’s Missed Primary Endpoint

3 months ago talkbio0Tagged Amyotrophic Lateral Sclerosis, Benefit, Corcept, DAZALS trial, dazucorilant, Phase 2 Clinical Trials, SURVEY.ALSFRSR, Survival

Corcept Therapeutics; dazucorilant; ALS; amyotrophic lateral sclerosis; DAZALS trial; survival benefit; phase 2 study; ALSFRS-R; ENCALS 2025

Forging the Future of Cell Therapy: Bayer and BlueRock’s Unique Journey

3 months ago talkbio0Tagged Bayer, bemdaneprocel, biotech partnerships, BlueRock Therapeutics, Cell Therapy, Identifier, Parkinson 's disease, Phase 3 trials, Regenerative Medicine, RMAT

cell therapy; Bayer; BlueRock Therapeutics; Parkinson’s disease; bemdaneprocel; biotech partnerships; RMAT designation; Phase 3 trials; regenerative medicine

Trump Administration Cancels Major Federal Funding for Moderna’s Bird Flu Vaccine

3 months ago talkbio0Tagged Administration occupational activities, bird flu vaccine, cancellation, CHARGE Syndrome, H5 avian influenza, HHS, Moderna, mRNA Vaccine, pandemic preparedness, Transplant Registry Unified Management Program

Trump administration; Moderna; bird flu vaccine; HHS; funding cancellation; mRNA vaccine; pandemic preparedness; H5 avian influenza

iTeos to Shut Down Operations After TIGIT Therapy Setback

3 months ago talkbio0Tagged asset, belrestotug, Clinical trial failure, ENT1, EOS-215, EOS-984, Exit, Failure (biologic function), immuno-oncology, iTeos, Obesity, Programs - Publication Format, Sales - occupational activity, SmithKline Beecham, TIGIT gene

iTeos Therapeutics; TIGIT failure; GSK exit; clinical trial failure; belrestotug; asset sale; immuno-oncology; EOS-984; EOS-215; ENT1 obesity program